Log In Help Join The Motley Fool

Qiagen (NYSE: QGEN)

$45.29

(-0.3%)

-$0.15

Price as of June 9, 2023, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Qiagen Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
QGEN	-2.84%	+24.36%	+4.45%	+2,214%
S&P	+2.57%	+53.56%	+8.96%	+536%

Qiagen Company Info

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

News & Analysis

The Fool has written over 100 articles on Qiagen.

Featured Article

Thermo Fisher Increases Its Buyout Price for Qiagen, but Investors Ask for More

Will Thermo Fisher be able to complete its deal to acquire Qiagen, or will shareholders vote it down?

Luis Sanchez CFA | Aug 4, 2020

Featured Article

Here's How Qiagen Trounced Q1 Estimates

The molecular diagnostics company blew past Wall Street's top- and bottom-line expectations in the first quarter for one main reason.

Keith Speights | May 7, 2020

Coronavirus Test-makers Ramp Up Production

Brian Orelli, PhD | Mar 18, 2020

Multiple companies have gained regulatory approvals in recent days.

Will COVID-19 Derail New Drugs?

David Haen | Mar 18, 2020

Disruptions in clinical trials and delayed regulatory decisions could slow the rate of new drug approvals.

FDA Warns About Potential Supply Chain Issues for Coronavirus Tests

Keith Speights | Mar 16, 2020

There's no shortage yet, but the FDA is working to address supply issues with a key component of COVID-19 diagnostics tests.

Here's Why Qiagen Jumped Higher Today

Brian Orelli, PhD | Mar 3, 2020

The diagnostic-test maker is being acquired for $11.5 billion.

Stock Market News: Tilray Comes Down; Thermo Fisher Makes a Big Buy

Dan Caplinger | Mar 3, 2020

The stock market was turbulent Tuesday morning.

Thermo Fisher Scientific to Spend $11.5 Billion Upgrading Its DNA Testing Game

Cory Renauer | Mar 3, 2020

The world's leading provider of scientific tools will buy QIAGEN and its growing menu of molecular diagnostic products.

Valuation

Earnings Transcripts

Qiagen NV (QGEN) Q3 2021 Earnings Call Transcript

QGEN earnings call for the period ending September 30, 2021.

Motley Fool Transcribers | Nov 4, 2021

Qiagen NV (QGEN) Q1 2021 Earnings Call Transcript

QGEN earnings call for the period ending March 31, 2021.

Motley Fool Transcribers | May 5, 2021

Qiagen NV (QGEN) Q4 2020 Earnings Call Transcript

QGEN earnings call for the period ending December 31, 2020.

Motley Fool Transcribers | Feb 10, 2021

Qiagen N.V. (QGEN) Q4 2019 Earnings Call Transcript

QGEN earnings call for the period ending December 31, 2019.

Motley Fool Transcribing | Feb 6, 2020

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services